Retapamulin

From Wikipedia, the free encyclopedia

Retapamulin
Systematic (IUPAC) name
(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl- 5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro- 3a,9-propano-3aH-cyclopenta[8]annulen-8-yl {[(1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] sulfanyl}acetate
Identifiers
CAS number	224452-66-8
ATC code	D06AX13
PubChem	6918462
Chemical data
Formula	C30H47NO4S
Mol. mass	517.77 g/mol
Pharmacokinetic data
Bioavailability	Low
Protein binding	94%
Metabolism	Hepatic, CYP3A4-mediated
Half life	Undetermined
Excretion	Undetermined
Therapeutic considerations
Licence data	EU, US
Pregnancy cat.	B(US)
Legal status	POM(UK) ℞-only(US)
Routes	Topical (ointment)

Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.

Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. On May 2007, retapamulin received EU approval from the European Medicines Agency for the same indication. It is marketed as an ointment under the brand names Altabax and Altargo (in other countries).

Clinical trials have demonstrated its efficacy against certain Gram-positive bacteria.^[1]

[edit] References